Research progress of radionuclide labeled fibroblast activation protein inhibitors PET imaging in cardiac diseases
10.3760/cma.j.cn321828-20220105-00002
- VernacularTitle:放射性核素标记成纤维细胞激活蛋白抑制剂PET显像应用于心脏疾病的研究进展
- Author:
Yufan GU
1
;
Lei WANG
;
Wei FANG
Author Information
1. 北京协和医学院、国家心血管病中心、中国医学科学院阜外医院核医学科，北京 100037
- Keywords:
Heart diseases;
Fibroblasts;
Antagonists and inhibitors;
Positron-emission tomography;
Trends
- From:
Chinese Journal of Nuclear Medicine and Molecular Imaging
2023;43(5):308-311
- CountryChina
- Language:Chinese
-
Abstract:
Myocardial fibrosis is one of the important pathological mechanisms in cardiac diseases. Non-invasive evaluation of fibrosis is of great clinical significance. Fibroblast activation protein (FAP) is selectively expressed in the membrane of activated fibroblasts. Radionuclide labeled FAP inhibitors (FAPI) serve as novel imaging agents, which specifically target to the process of fibrotic remodeling. This article reviews the research progress of radionuclide labeled FAPI PET imaging in cardiac diseases.
